Monte Rosa Therapeutics vs Kymera Therapeutics
GLUE and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GLUE and KYMR compare
Kymera Therapeutics is the larger company, worth 14 times as much as Monte Rosa Therapeutics ($10.9B against $799M).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −61.3% for Monte Rosa Therapeutics).
Monte Rosa Therapeutics keeps more of each dollar of sales as profit, with a net margin of −186% compared with −342% at Kymera Therapeutics.
Kymera Therapeutics scores higher on the StockData Score (9 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GLUE | KYMR |
|---|---|---|
| Size and price | ||
| Market cap | $799M | $10.9B |
| Share price | $9.37 | $127.57 |
| Change, 1 year | −33.8% | 101% |
| Change, 5 years | −52.1% | 107% |
| Beta (5Y) | 1.83 | 1.91 |
| Employees | 150 | 238 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.4× (better) | 107× |
| P/B | 1.6× (better) | 6.7× |
| FCF yield | −21.8% | −2.7% (better) |
| Fair value | $8.37 | $36.81 |
| Margin of safety | −11.9% (better) | −247% |
| Growth | ||
| Revenue growth (TTM) | −61.3% | 134% (better) |
| Revenue growth, 5Y average | – | 2.9% |
| Net income growth (TTM) | −725% | – |
| EPS growth (TTM) | −660% | – |
| Profitability | ||
| Gross margin | – | 0.00% |
| Operating margin | −214% (better) | −396% |
| Net margin | −186% (better) | −342% |
| FCF margin | −248% (better) | −283% |
| Return on equity | −35.3% | −27.3% (better) |
| Return on invested capital | – | −59.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.32 | 11.13 (better) |
| Altman Z-score | 1.63 | 41.65 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 114% |
| Held by insiders | 11.5% | 38.3% |
| Insider net buying, 12 months | −$4.1M (better) | −$301M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 27.6% | 16.0% |
Go deeper
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.